Skip to main
  1. Stocks
  2. Liquidia Technologies Inc
  3. Forecast
LQDA

LQDA Stock Forecast & Price Target

LQDA Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 22%
Hold 22%
Sell 11%
Strong Sell 0%

Bulls say

Liquidia is well positioned because the October 2026 settlement with United Therapeutics removes a major legal overhang, preserves full YUTREPIA economics in PAH, and lets management concentrate on a clearer franchise strategy. Commercially, YUTREPIA has shown durable traction with five straight quarters of sales growth, 3Q26 net product sales up 31% QoQ to about $222.7 million, more than 70% of September referrals carrying a PAH diagnosis, and cumulative patient starts estimated at roughly 6,000–6,400 by the end of October. Fundamentally, the company also has multiple catalysts beyond the launch, including a Phase 4 program beginning in 4Q26, LTI-403 primary completion expected in 2Q27, and L606 supporting a potential NDA submission in 2029, while 3Q26 cash of about $396 million and a reported non-GAAP adjusted EBITDA of $140.5 million provide financial flexibility.

Bears say

Liquidia is a difficult commercial story because Yutrepia enters a pulmonary arterial hypertension market already dominated by established players such as United Therapeutics and Actelion, with Tyvaso and Tyvaso DPI posing direct, well-entrenched competitive threats. The company must also fund the commercialization of Yutrepia and L606, if approved, which implies significant and rising operating expenses before any meaningful scale is achieved. That funding burden creates a high likelihood of substantial capital needs and potentially dilutive financings, making the equity structurally unattractive on a fundamental basis.

LQDA has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 22% recommend Buy, 22% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.

LQDA Analyst Forecast & Price Prediction

Get the latest LQDA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in LQDA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Liquidia Technologies Inc (LQDA) Forecast

Analysts have given LQDA a Buy based on their latest research and market trends.

According to 9 analysts, LQDA has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $61.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $61.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Liquidia Technologies Inc (LQDA)


LQDA Analyst Forecast & Price Prediction

Get the latest LQDA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in LQDA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover LQDA stock data and trends